Surveillance of Medication Use During Pregnancy in the Mini-Sentinel Program

Maternal and Child Health Journal

Volumn 20, Issue 4, 2016, Pages 895-903

  Andrade, Susan E ^a   Toh, Sengwee ^b   Houstoun, Monika ^c   Mott, Katrina ^c   Pitts, Marilyn ^c   Kieswetter, Caren ^c   Ceresa, Carrie ^c   Haffenreffer, Katherine ^b   Reichman, Marsha E ^c  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Pregnancy; Prescription medications; Surveillance

Indexed keywords

PRESCRIPTION DRUG;

ADULT; COHORT ANALYSIS; DRUG UTILIZATION; FACTUAL DATABASE; FEMALE; HUMAN; MATERNAL AGE; MIDDLE AGED; NEWBORN; PREGNANCY; PRENATAL CARE; PRESCRIPTION; PREVALENCE; PROCEDURES; STATISTICS AND NUMERICAL DATA; UNITED STATES; YOUNG ADULT;

ADULT; COHORT STUDIES; DATABASES, FACTUAL; DRUG PRESCRIPTIONS; DRUG UTILIZATION; FEMALE; HUMANS; INFANT, NEWBORN; MATERNAL AGE; MIDDLE AGED; PREGNANCY; PREGNANCY TRIMESTERS; PRENATAL CARE; PRESCRIPTION DRUGS; PREVALENCE; UNITED STATES; YOUNG ADULT;

EID: 84961187778     PISSN: 10927875     EISSN: 15736628     Source Type: Journal    
DOI: 10.1007/s10995-015-1878-8     Document Type: Article

References (19)

1. Behrman, R. E., Benner, J. S., Brown, J. S., McClellan, M., Woodcock, J., & Platt, R. (2011). Developing the sentinel system—A national resource for evidence development. New England Journal of Medicine,364, 498–499. doi:10.1056/NEJMp1014427.
2. Platt, R., Carnahan, R. M., Brown, J. S., et al. (2012). The U.S. Food and Drug Administration’s Mini-Sentinel program: Status and direction. Pharmacoepidemiology and Drug Safety,21(Suppl 1), 1–8. doi:10.1002/pds.2343.
3. Mitchell, A. A. (2003). Systematic identification of drugs that cause birth defects—A new opportunity. New England Journal of Medicine,349(26), 2556–2559.
4. Rosenfield, A., Charo, R. A., & Chavkin, W. (2008). Moving forward on reproductive health. New England Journal of Medicine,359(18), 1869–1871. doi:10.1056/NEJMp0806807.
5. Andrade, S. E., Gurwitz, J. H., Davis, R. L., et al. (2004). Prescription drug use in pregnancy. American Journal of Obstetrics and Gynecology,191, 398–407.
6. Mitchell, A. A., Gilboa, S. M., Werler, M. M., Kelley, K. E., Louik, C., Hernández-Díaz, S., et al. (2011). Medication use during pregnancy, with particular focus on prescription drugs: 1976–2008. Am J Obstet Gynecol.,205(1), 51.e1–51.e8. doi:10.1016/j.ajog.2011.02.029.
7. Riley, E. H., Fuentes-Afflick, E., Jackson, R. A., et al. (2005). Correlates of prescription drug use during pregnancy. Journal of Womens Health (Larchmt),14(5), 401–409.
8. Andrade, S. E., Raebel, M. A., Morse, A. N., et al. (2006). Use of prescription medications with a potential for fetal harm among pregnant women. Pharmacoepidemiology and Drug Safety,15(8), 546–554.
9. Cooper, W. O., Hickson, G. B., & Ray, W. A. (2004). Prescriptions for contraindicated category X drugs in pregnancy among women enrolled in TennCare. Paediatric and Perinatal Epidemiology,18(2), 106–111.
10. Curtis, L. H., Weiner, M. G., Boudreau, D. M., et al. (2012). Design considerations, architecture, and use of the Mini-Sentinel distributed data system. Pharmacoepidemiology and Drug Safety,21(Suppl 1), 23–31. doi:10.1002/pds.2336.
11. Brown, J., Kahn, M., & Toh, S. (2013). Data quality assessment for comparative effectiveness research in distributed data networks. Medical Care,51(8 Suppl 3), S22–S29. doi:10.1097/MLR.0b013e31829b1e2c.
12. Rosati, K., Evans, B., & McGraw, D. (2014). HIPAA and common rule compliance in the Mini-Sentinel pilot, white paper. http://www.mini-sentinel.org/work_products/About_Us/HIPAA_and_CommonRuleCompliance_in_the_Mini-SentinelPilot.pdf [serial online] 2011. Accessed 9 June 2014.
13. Kawai, A. T., Li, L., & Kulldorff, M., et al. (2014). Mini-Sentinel CBER/PRISM surveillance protocol influenza vaccines and pregnancy outcome. Version 2. http://www.mini-sentinel.org/work_products/PRISM/Mini-Sentinel_PRISM_Influenza-Vaccines-and-Pregnancy-Outcomes-Protocol.pdf. Accessed 7 July 2014.
14. Andrade, S. E., Davis, R. L., Cheetham, T. C., et al. (2012). Medication exposure in pregnancy risk evaluation program. Maternal and Child Health Journal,16(7), 1349–1354. doi:10.1007/s10995-011-0902-x.
15. Li, Q., Andrade, S. E., Cooper, W. O., et al. (2013). Validation of an algorithm to estimate gestational age in electronic health plan databases. Pharmacoepidemiology and Drug Safety,22(5), 524–532. doi:10.1002/pds.3407.
16. Raebel, M. A., Ellis, J. L., & Andrade, S. E. (2005). Evaluation of gestational age and admission date assumptions used to determine prenatal drug exposure from administrative data. Pharmacoepidemiology and Drug Safety,14(12), 829–836.
17. Martin, J. A., Hamilton, B. E., Osterman, J. K., et al. (2013). Births: Final data for 2012. National vital statistics reports (Vol. 62, No. 2). Hyattsville, MD: National Center for Health Statistics.
18. Bateman, B. T., Hernandez-Diaz, S., Huybrechts, K. F., Palmsten, K., Mogun, H., Ecker, J. L., et al. (2012). Patterns of outpatient antihypertensive medication use during pregnancy in a Medicaid population. Hypertension,60(4), 913–920. doi:10.1161/HYPERTENSIONAHA.112.197095.
19. Andrade, S. E., Raebel, M. A., Brown, J., et al. (2008). Outpatient use of cardiovascular drugs during pregnancy. Pharmacoepidemiology and Drug Safety,17(3), 240–247. doi:10.1002/pds.1550.